Journal
MOVEMENT DISORDERS
Volume 32, Issue 8, Pages 1131-1138Publisher
WILEY
DOI: 10.1002/mds.27072
Keywords
botulinum toxin; dystonia; blepharospasm; hemifacial spasm; spasticity; tremor; tics
Categories
Funding
- Allergan, Inc
- Dystonia Coalition
- Dystonia Medical Research Foundation
- Revance Therapeutics, Inc.
Ask authors/readers for more resources
Botulinun neurotoxin (BoNT) has emerged as one of the most multipurpose therapeutic agents in modern medicine with more clinical applications than any other drug currently on the market. Initially developed in the treatment of strabismus and neurologic movement disorders, the use of botulinun neurotoxin has been expanding during the past 3 decades to include the treatment of a variety of ophthalmologic, gastrointestinal, urologic, orthopedic, dermatologic, dental, secretory, painful, cosmetic, and other conditions. In addition to onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), and RimabotulinumtoxinB (Myobloc or NeuroBloc) there are other novel botulinun neurotoxin products currently in development. With a better understanding of the cellular mechanisms of botulinun neurotoxin and advances in biotechnology, future botulinun neurotoxin products will likely be even more effective and customized to the specific indication and tailored to the needs of the patients. (C) 2017 International Parkinson and Movement Disorder Society
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available